Target Card Uniprot Example: P23975

bemiparin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
heparin derivatives including low molecular mass heparins	4840	9041-08-1

Description:

Molecule	Description
Synonyms: tinzaparin ardeparin sodium dalteparin sodium tinzaparin sodium bemiparin bemiparin sodium	A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed) Molecular weight: Formula: None CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
3.50	TU	P
2.50	TU	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 22, 1994	FDA	PFIZER INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary embolism	211.00	12.80	246	22911	101458	50480509
Hepatocellular injury	144.74	12.80	109	23048	25838	50556129
Drug ineffective	136.60	12.80	106	23051	819227	49762740
Toxic epidermal necrolysis	123.36	12.80	91	23066	20901	50561066
Acute kidney injury	120.91	12.80	299	22858	227759	50354208
Thrombocytopenia	106.22	12.80	201	22956	127472	50454495
Heparin-induced thrombocytopenia	94.97	12.80	43	23114	3922	50578045
General physical health deterioration	83.14	12.80	194	22963	142240	50439727
Cholestasis	78.42	12.80	76	23081	25325	50556642
Deep vein thrombosis	73.16	12.80	125	23032	73179	50508788
Needle issue	70.38	12.80	43	23114	7232	50574735
Anaemia	70.19	12.80	264	22893	252192	50329775
Drug intolerance	65.13	12.80	11	23146	219093	50362874
Arthralgia	62.85	12.80	65	23092	438637	50143330
Rheumatoid arthritis	58.39	12.80	11	23146	202539	50379428
Product dose omission issue	57.43	12.80	8	23149	183830	50398137
Neutropenic sepsis	54.68	12.80	48	23109	14099	50567868
Arthropathy	54.00	12.80	5	23152	157901	50424066
Drug reaction with eosinophilia and systemic symptoms	52.64	12.80	65	23092	28359	50553608
Biliary sepsis	51.42	12.80	18	23139	832	50581135
Rash maculo-papular	51.08	12.80	62	23095	26579	50555388
Blue toe syndrome	51.06	12.80	15	23142	391	50581576
Blood creatine increased	50.14	12.80	30	23127	4857	50577110
Arteriovenous fistula occlusion	47.65	12.80	14	23143	365	50581602
Therapeutic product effect decreased	47.35	12.80	4	23153	136046	50445921
Jaundice	46.65	12.80	59	23098	26370	50555597
Venous pressure jugular decreased	45.95	12.80	9	23148	35	50581932
Neutropenia	45.49	12.80	160	22997	147805	50434162
Abdominal discomfort	45.03	12.80	25	23132	231616	50350351
Hyperthyroidism	44.45	12.80	40	23117	12135	50569832
Melaena	44.32	12.80	58	23099	26806	50555161
Vessel puncture site bruise	43.92	12.80	13	23144	348	50581619
Dermatitis exfoliative	43.71	12.80	28	23129	5114	50576853
Sinusitis	43.67	12.80	12	23145	170546	50411421
Febrile neutropenia	43.34	12.80	120	23037	97547	50484420
Agranulocytosis	42.95	12.80	51	23106	21370	50560597
Gamma-glutamyltransferase increased	41.37	12.80	59	23098	29564	50552403
Glossodynia	41.33	12.80	3	23154	115566	50466401
Pituitary tumour	39.92	12.80	15	23142	850	50581117
Adrenal suppression	39.81	12.80	15	23142	857	50581110
Headache	39.38	12.80	111	23046	506424	50075543
Ovarian hyperstimulation syndrome	38.81	12.80	22	23135	3222	50578745
Thrombosis	38.08	12.80	81	23076	55752	50526215
Joint swelling	37.77	12.80	34	23123	245252	50336715
Systemic lupus erythematosus	37.71	12.80	9	23148	140613	50441354
Haematoma	37.19	12.80	57	23100	30453	50551514
Haemoglobin decreased	36.90	12.80	135	23022	127081	50454886
Alopecia	36.51	12.80	35	23122	245012	50336955
Blood loss anaemia	36.33	12.80	30	23127	8109	50573858
Drug hypersensitivity	36.08	12.80	37	23120	250973	50330994
Hypothalamo-pituitary disorder	35.71	12.80	13	23144	674	50581293
Body dysmorphic disorder	34.25	12.80	10	23147	255	50581712
Ascites	34.24	12.80	60	23097	35801	50546166
Activated partial thromboplastin time prolonged	33.71	12.80	26	23131	6376	50575591
Sepsis	33.57	12.80	135	23022	132790	50449177
Malignant neoplasm progression	33.53	12.80	87	23070	68037	50513930
Discomfort	33.17	12.80	5	23152	108375	50473592
Blood creatinine increased	32.23	12.80	92	23065	76068	50505899
Pancytopenia	32.21	12.80	98	23059	83932	50498035
Pyrexia	31.93	12.80	289	22868	379914	50202053
Perforation	31.43	12.80	13	23144	951	50581016
Abdominal wall haematoma	31.41	12.80	18	23139	2690	50579277
Treatment failure	31.14	12.80	12	23145	137625	50444342
Cytokine release syndrome	30.79	12.80	28	23129	8606	50573361
Depression	30.50	12.80	19	23138	165404	50416563
Abdominal wall haemorrhage	30.41	12.80	8	23149	137	50581830
Cardiac failure	30.39	12.80	90	23067	75950	50506017
Pneumothorax traumatic	29.48	12.80	8	23149	155	50581812
Pain	29.31	12.80	151	23006	578752	50003215
Fatigue	29.26	12.80	197	22960	707404	49874563
Epistaxis	28.77	12.80	79	23078	63875	50518092
Hyperkalaemia	28.54	12.80	66	23091	48023	50533944
Drug interaction	28.34	12.80	172	22985	199449	50382518
Wound	27.91	12.80	7	23150	105787	50476180
Cardiomyopathy acute	27.82	12.80	8	23149	193	50581774
Haematoma muscle	27.80	12.80	11	23146	717	50581250
Joint ankylosis	27.29	12.80	11	23146	753	50581214
Gastric antral vascular ectasia	27.18	12.80	10	23147	534	50581433
Gastrointestinal haemorrhage	26.70	12.80	84	23073	73237	50508730
Electrolyte imbalance	26.67	12.80	36	23121	17133	50564834
Intra-abdominal haemorrhage	26.41	12.80	15	23142	2205	50579762
Premature baby	26.31	12.80	37	23120	18300	50563667
Exposure during pregnancy	25.98	12.80	117	23040	120898	50461069
Pericarditis	25.58	12.80	3	23154	78686	50503281
Catheter site thrombosis	25.49	12.80	7	23150	142	50581825
Cerebral haemorrhage	25.48	12.80	45	23112	27007	50554960
Bronchopulmonary dysplasia	25.15	12.80	8	23149	274	50581693
Haemorrhagic erosive gastritis	25.15	12.80	8	23149	274	50581693
Bone marrow eosinophilic leukocyte count increased	25.03	12.80	5	23152	22	50581945
Psychiatric decompensation	25.02	12.80	12	23145	1246	50580721
Muscle haemorrhage	24.88	12.80	16	23141	2942	50579025
Musculoskeletal stiffness	24.75	12.80	14	23143	128467	50453500
Disease progression	24.70	12.80	98	23059	95768	50486199
Cholecystitis	24.53	12.80	31	23126	13840	50568127
Neoplasm progression	24.30	12.80	46	23111	29111	50552856
Fracture blisters	24.20	12.80	6	23151	80	50581887
Allergic hepatitis	24.03	12.80	5	23152	28	50581939
Feeling abnormal	23.71	12.80	14	23143	125478	50456489
Constipation	23.24	12.80	155	23002	185553	50396414
Renal tubular acidosis	22.77	12.80	12	23145	1522	50580445
Contraindicated product administered	22.49	12.80	21	23136	148937	50433030
Multiple organ dysfunction syndrome	22.46	12.80	62	23095	50275	50531692
Pleural effusion	22.39	12.80	85	23072	81369	50500598
Femoral neck fracture	22.34	12.80	22	23135	7468	50574499
Hepatitis cholestatic	22.13	12.80	20	23137	6097	50575870
Haemoptysis	22.13	12.80	41	23116	25532	50556435
Pneumobilia	22.07	12.80	6	23151	117	50581850
Retroperitoneal haemorrhage	21.93	12.80	14	23143	2542	50579425
Embolism	21.78	12.80	21	23136	6947	50575020
Erythema	21.29	12.80	127	23030	146287	50435680
International normalised ratio increased	21.11	12.80	55	23102	43097	50538870
Respiratory disorder	20.97	12.80	45	23112	31142	50550825
Granulomatous liver disease	20.83	12.80	9	23148	734	50581233
Foetal growth restriction	20.77	12.80	20	23137	6607	50575360
Therapeutic product effect incomplete	20.66	12.80	8	23149	91507	50490460
Thrombophlebitis	20.55	12.80	16	23141	3977	50577990
Hyperlipasaemia	20.33	12.80	8	23149	514	50581453
Eosinophilia	20.17	12.80	33	23124	18619	50563348
Caesarean section	20.16	12.80	30	23127	15609	50566358
Diarrhoea haemorrhagic	20.07	12.80	21	23136	7654	50574313
Leukopenia	19.84	12.80	72	23085	67456	50514511
Limbal swelling	19.77	12.80	4	23153	19	50581948
Cholestatic liver injury	19.68	12.80	12	23145	2009	50579958
Cardiac failure congestive	19.68	12.80	7	23150	84375	50497592
Impaired healing	19.64	12.80	4	23153	69782	50512185
Anaemia folate deficiency	19.52	12.80	6	23151	183	50581784
Diarrhoea	19.39	12.80	377	22780	588099	49993868
Phlebitis	19.33	12.80	18	23139	5702	50576265
Cerebral infarction	19.15	12.80	35	23122	21569	50560398
Hypersensitivity	19.08	12.80	44	23113	215117	50366850
Gastric ulcer	18.23	12.80	34	23123	21271	50560696
Haemangioma congenital	18.06	12.80	7	23150	432	50581535
Protein S decreased	17.99	12.80	4	23153	32	50581935
Alanine aminotransferase increased	17.89	12.80	84	23073	88275	50493692
Faecaloma	17.79	12.80	19	23138	7089	50574878
Protein C decreased	17.67	12.80	4	23153	35	50581932
Blood alkaline phosphatase increased	17.51	12.80	47	23110	37479	50544488
Acute generalised exanthematous pustulosis	17.45	12.80	21	23136	8917	50573050
Subcutaneous haematoma	17.38	12.80	10	23147	1505	50580462
Lordosis	17.27	12.80	6	23151	271	50581696
Maternal drugs affecting foetus	17.20	12.80	16	23141	5061	50576906
Intra-abdominal haematoma	17.13	12.80	10	23147	1547	50580420
Premature delivery	16.90	12.80	35	23122	23628	50558339
Chemotherapeutic drug level increased	16.82	12.80	5	23152	136	50581831
Cerebral haematoma	16.81	12.80	13	23144	3198	50578769
Haemolysis	16.71	12.80	17	23140	5999	50575968
Chest X-ray abnormal	16.67	12.80	14	23143	3871	50578096
Hypokalaemia	16.62	12.80	82	23075	87910	50494057
Haemorrhage	16.57	12.80	58	23099	53383	50528584
Visual acuity reduced transiently	16.54	12.80	5	23152	144	50581823
Gastrointestinal tract adenoma	16.32	12.80	6	23151	320	50581647
Skin warm	16.19	12.80	15	23142	4720	50577247
Varices oesophageal	16.17	12.80	12	23145	2777	50579190
Toxicity to various agents	16.12	12.80	47	23110	212452	50369515
Abdominal pain	16.07	12.80	172	22985	236056	50345911
Magnetic resonance imaging head abnormal	15.91	12.80	10	23147	1767	50580200
Blood cholesterol increased	15.89	12.80	3	23154	55212	50526755
Interstitial lung disease	15.88	12.80	57	23100	53119	50528848
Infantile haemangioma	15.82	12.80	4	23153	58	50581909
Ill-defined disorder	15.66	12.80	3	23154	54651	50527316
Infusion related reaction	15.58	12.80	34	23123	169523	50412444
Intracranial pressure increased	15.58	12.80	14	23143	4238	50577729
Persecutory delusion	15.50	12.80	11	23146	2376	50579591
Cardiac hypertrophy	15.43	12.80	8	23149	981	50580986
Acidosis	15.21	12.80	21	23136	10206	50571761
Normal newborn	15.21	12.80	17	23140	6674	50575293
Gastrointestinal disorder	14.62	12.80	13	23144	94443	50487524
Upper gastrointestinal haemorrhage	14.24	12.80	26	23131	16009	50565958
Stevens-Johnson syndrome	14.18	12.80	31	23126	21721	50560246
Renal pain	14.03	12.80	15	23142	5604	50576363
Vascular occlusion	13.92	12.80	7	23150	806	50581161
Bone marrow oedema	13.91	12.80	7	23150	807	50581160
Hypoaesthesia	13.89	12.80	23	23134	127234	50454733
Reticulocyte count increased	13.88	12.80	7	23150	811	50581156
Post procedural haematoma	13.86	12.80	8	23149	1212	50580755
Thrombosis prophylaxis	13.84	12.80	3	23154	21	50581946
CSF white blood cell count decreased	13.84	12.80	3	23154	21	50581946
Insomnia	13.76	12.80	38	23119	174827	50407140
Mucosal inflammation	13.70	12.80	45	23112	40097	50541870
Gestational diabetes	13.70	12.80	17	23140	7448	50574519
Clostridium difficile colitis	13.57	12.80	27	23130	17715	50564252
Foetal growth abnormality	13.49	12.80	3	23154	24	50581943
Humerus fracture	13.43	12.80	17	23140	7601	50574366
Red cell distribution width increased	13.37	12.80	18	23139	8541	50573426
Cholelithiasis	13.35	12.80	43	23114	37930	50544037
Rash	13.32	12.80	132	23025	437339	50144628
Anxiety disorder	13.27	12.80	12	23145	3661	50578306
Injection site erythema	13.27	12.80	9	23148	74927	50507040
Transaminases increased	13.14	12.80	35	23122	27789	50554178
Asthma	13.00	12.80	13	23144	89324	50492643
HER2 positive breast cancer	12.94	12.80	5	23152	306	50581661

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	188.97	13.67	77	21336	3403	29549711
General physical health deterioration	159.66	13.67	275	21138	102582	29450532
Appendicitis	126.56	13.67	79	21334	8700	29544414
Drug ineffective	103.88	13.67	68	21345	363102	29190012
Cardiogenic shock	97.85	13.67	93	21320	19097	29534017
Pulmonary embolism	96.27	13.67	187	21226	76347	29476767
Hepatocellular injury	77.52	13.67	86	21327	21157	29531957
Toxic epidermal necrolysis	75.93	13.67	79	21334	18074	29535040
Sepsis	66.05	13.67	240	21173	142442	29410672
Stress	63.39	13.67	78	21335	21412	29531702
Ascites	60.73	13.67	101	21312	36518	29516596
Thrombocytopenia	60.05	13.67	224	21189	134599	29418515
Heparin-induced thrombocytopenia	59.90	13.67	40	21373	4939	29548175
Lymph node calcification	59.04	13.67	15	21398	135	29552979
Acute kidney injury	58.28	13.67	359	21054	264908	29288206
Multiple organ dysfunction syndrome	54.96	13.67	133	21280	62983	29490131
Abdominal pain	51.45	13.67	214	21199	135143	29417971
Abdominal distension	49.13	13.67	105	21308	45806	29507308
Hyponatraemia	49.02	13.67	133	21280	67500	29485614
Toxicity to various agents	46.17	13.67	35	21378	173626	29379488
Drug abuse	43.22	13.67	4	21409	79879	29473235
Haemorrhage	37.11	13.67	93	21320	44979	29508135
Pulmonary sarcoidosis	36.82	13.67	14	21399	513	29552601
Aplasia	35.81	13.67	27	21386	4036	29549078
Death	32.29	13.67	133	21280	341951	29211163
Suspected product quality issue	31.29	13.67	9	21404	134	29552980
Neutropenia	30.52	13.67	181	21232	131530	29421584
Hepatic haematoma	29.44	13.67	11	21402	384	29552730
Ventricular fibrillation	29.41	13.67	46	21367	15787	29537327
Bronchial obstruction	29.26	13.67	16	21397	1375	29551739
Bronchial disorder	29.07	13.67	15	21398	1146	29551968
Product dose omission issue	28.84	13.67	17	21396	96366	29456748
Feeling abnormal	28.72	13.67	3	21410	54442	29498672
Dizziness	28.63	13.67	59	21354	189625	29363489
Splenic vein thrombosis	28.50	13.67	11	21402	420	29552694
Haematemesis	28.28	13.67	58	21355	24568	29528546
Peritoneal haematoma	27.96	13.67	7	21406	59	29553055
Mucosal inflammation	27.92	13.67	67	21346	31528	29521586
Febrile neutropenia	27.13	13.67	156	21257	112084	29441030
Cholestasis	26.64	13.67	55	21358	23407	29529707
Shock haemorrhagic	25.50	13.67	33	21380	9518	29543596
Cardiac failure congestive	25.13	13.67	12	21401	76569	29476545
Chondrocalcinosis	24.85	13.67	9	21404	287	29552827
Floppy infant	24.23	13.67	7	21406	106	29553008
Oesophagitis	24.06	13.67	36	21377	11887	29541227
Genitalia external ambiguous	23.75	13.67	8	21405	205	29552909
Septic shock	22.99	13.67	98	21315	62462	29490652
Metastatic malignant melanoma	22.84	13.67	15	21398	1800	29551314
Depression	22.80	13.67	17	21396	85130	29467984
Portal vein thrombosis	22.75	13.67	19	21394	3290	29549824
Mucosal disorder	22.71	13.67	14	21399	1506	29551608
Muscle haemorrhage	22.48	13.67	19	21394	3343	29549771
Hyperkalaemia	22.43	13.67	96	21317	61296	29491818
Haemorrhagic disorder	22.41	13.67	10	21403	553	29552561
Rash maculo-papular	21.99	13.67	52	21361	24237	29528877
Embolism	21.91	13.67	26	21387	6870	29546244
Congenital bladder anomaly	21.80	13.67	8	21405	265	29552849
Hypertrophic osteoarthropathy	21.61	13.67	6	21407	78	29553036
Lung cancer metastatic	21.10	13.67	16	21397	2411	29550703
Pancytopenia	21.01	13.67	117	21296	83051	29470063
Eosinophil percentage decreased	20.52	13.67	6	21407	95	29553019
Haematoma	20.26	13.67	49	21364	23163	29529951
Foetal hypokinesia	19.28	13.67	8	21405	370	29552744
Coagulation factor VII level decreased	19.26	13.67	6	21407	119	29552995
Klebsiella infection	19.01	13.67	25	21388	7324	29545790
Compartment syndrome	18.79	13.67	15	21398	2437	29550677
Jaundice cholestatic	18.76	13.67	19	21394	4207	29548907
Prothrombin time shortened	18.69	13.67	12	21401	1386	29551728
Neonatal respiratory depression	18.61	13.67	8	21405	404	29552710
Thrombocytosis	18.52	13.67	17	21396	3336	29549778
Pulmonary artery thrombosis	18.50	13.67	9	21404	606	29552508
Respiratory disorder neonatal	18.48	13.67	12	21401	1413	29551701
Bladder tamponade	17.73	13.67	8	21405	454	29552660
Insomnia	17.67	13.67	23	21390	88738	29464376
Pyrexia	17.23	13.67	298	21115	287324	29265790
Blood pressure diastolic increased	17.15	13.67	17	21396	3669	29549445
Haemolytic anaemia	16.98	13.67	27	21386	9392	29543722
Neutropenic infection	16.93	13.67	11	21402	1296	29551818
Cardiac flutter	16.75	13.67	12	21401	1658	29551456
Butterfly rash	16.30	13.67	5	21408	94	29553020
Wrong strength	16.15	13.67	5	21408	97	29553017
Epistaxis	16.00	13.67	77	21336	51627	29501487
Hypokalaemia	15.71	13.67	75	21338	50128	29502986
Lung disorder	15.65	13.67	53	21360	30309	29522805
Therapeutic product effect prolonged	15.40	13.67	6	21407	235	29552879
Abdominal sepsis	15.26	13.67	9	21404	893	29552221
Myositis	15.24	13.67	27	21386	10256	29542858
Hepatic cytolysis	15.15	13.67	24	21389	8323	29544791
Anxiety	15.14	13.67	24	21389	85341	29467773
Gamma-glutamyltransferase increased	14.97	13.67	48	21365	26689	29526425
Vomiting	14.96	13.67	226	21187	212034	29341080
Constipation	14.95	13.67	137	21276	114023	29439091
Myalgia	14.92	13.67	19	21394	74000	29479114
Malignant neoplasm progression	14.88	13.67	98	21315	73761	29479353
Product communication issue	14.81	13.67	5	21408	129	29552985
Therapeutic product effect incomplete	14.78	13.67	5	21408	39300	29513814
Respiratory tract infection	14.70	13.67	34	21379	15617	29537497
Reading disorder	14.68	13.67	7	21406	451	29552663
Cerebral haemorrhage	14.59	13.67	53	21360	31373	29521741
Large intestine perforation	14.54	13.67	22	21391	7334	29545780
Miosis	14.50	13.67	23	21390	7986	29545128
Penile necrosis	14.48	13.67	4	21409	51	29553063
Lower respiratory tract infection	14.31	13.67	47	21366	26455	29526659
Hyperthermia	14.28	13.67	25	21388	9405	29543709
Hepatitis cholestatic	14.17	13.67	21	21392	6872	29546242
Haemoglobin decreased	14.16	13.67	130	21283	108245	29444869
Leukopenia	14.15	13.67	78	21335	55125	29497989
Soft tissue sarcoma	14.13	13.67	4	21409	56	29553058
Lactic acidosis	14.03	13.67	51	21362	30196	29522918
Hospitalisation	13.90	13.67	8	21405	45980	29507134
Headache	13.77	13.67	72	21341	173935	29379179
Agranulocytosis	13.72	13.67	39	21374	20301	29532813

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary embolism	267.59	11.64	395	40971	145961	64311405
General physical health deterioration	234.82	11.64	448	40918	203977	64253389
Drug ineffective	198.90	11.64	150	41216	840097	63617269
Appendicolith	198.19	11.64	77	41289	3392	64453974
Hepatocellular injury	196.40	11.64	190	41176	45045	64412321
Toxic epidermal necrolysis	176.37	11.64	164	41202	37002	64420364
Acute kidney injury	149.28	11.64	626	40740	448614	64008752
Thrombocytopenia	145.11	11.64	391	40975	223410	64233956
Heparin-induced thrombocytopenia	137.91	11.64	79	41287	8400	64448966
Appendicitis	106.24	11.64	80	41286	13489	64443877
Sepsis	96.67	11.64	346	41020	229995	64227371
Cholestasis	94.93	11.64	130	41236	44742	64412624
Ascites	85.10	11.64	147	41219	61854	64395512
Cardiogenic shock	84.28	11.64	104	41262	32323	64425043
Toxicity to various agents	81.68	11.64	68	41298	363445	64093921
Multiple organ dysfunction syndrome	73.60	11.64	185	41181	101228	64356138
Drug intolerance	70.40	11.64	17	41349	187975	64269391
Arthralgia	68.87	11.64	111	41255	442149	64015217
Drug abuse	68.76	11.64	4	41362	132370	64324996
Anaemia	65.42	11.64	441	40925	378239	64079127
Product dose omission issue	63.11	11.64	23	41343	194724	64262642
Rash maculo-papular	61.28	11.64	109	41257	46917	64410449
Deep vein thrombosis	60.38	11.64	176	41190	105006	64352360
Neutropenia	57.33	11.64	304	41062	239320	64218046
Lymph node calcification	53.96	11.64	16	41350	303	64457063
Arthropathy	53.80	11.64	7	41359	120960	64336406
Therapeutic product effect decreased	52.96	11.64	6	41360	115345	64342021
Abdominal pain	51.64	11.64	360	41006	312015	64145351
Febrile neutropenia	51.13	11.64	247	41119	187410	64269956
Headache	50.92	11.64	172	41194	529295	63928071
Gamma-glutamyltransferase increased	49.10	11.64	101	41265	48409	64408957
Haematoma	48.84	11.64	98	41268	46152	64411214
Neutropenic sepsis	48.57	11.64	67	41299	23205	64434161
Malignant neoplasm progression	48.50	11.64	171	41195	112700	64344666
Hyperkalaemia	45.87	11.64	156	41210	100973	64356393
Depression	45.32	11.64	31	41335	183260	64274106
Embolism	45.00	11.64	47	41319	12188	64445178
Pancytopenia	44.47	11.64	196	41170	143113	64314253
Constipation	44.37	11.64	275	41091	229062	64228304
Sinusitis	44.36	11.64	19	41347	145909	64311457
Abdominal discomfort	43.55	11.64	32	41334	182290	64275076
Drug reaction with eosinophilia and systemic symptoms	42.60	11.64	102	41264	54115	64403251
Blood loss anaemia	41.76	11.64	48	41318	13844	64443522
Abdominal distension	41.72	11.64	146	41220	95848	64361518
Epistaxis	41.58	11.64	148	41218	97983	64359383
Cardiac failure congestive	41.32	11.64	16	41350	130564	64326802
Feeling abnormal	41.25	11.64	17	41349	133585	64323781
Blue toe syndrome	40.88	11.64	15	41351	563	64456803
Agranulocytosis	40.36	11.64	81	41285	38148	64419218
Haemoglobin decreased	40.32	11.64	238	41128	194825	64262541
Biliary sepsis	39.53	11.64	19	41347	1409	64455957
Joint swelling	39.50	11.64	48	41318	215334	64242032
Haemorrhage	39.19	11.64	126	41240	79225	64378141
Rheumatoid arthritis	39.03	11.64	29	41337	164265	64293101
Hyperthyroidism	38.93	11.64	53	41313	18126	64439240
Jaundice	38.90	11.64	92	41274	48420	64408946
Muscle haemorrhage	38.68	11.64	31	41335	5722	64451644
Pyrexia	38.58	11.64	536	40830	558108	63899258
Blood creatine increased	38.55	11.64	36	41330	8156	64449210
Melaena	38.11	11.64	97	41269	53451	64403915
Arteriovenous fistula occlusion	37.92	11.64	14	41352	535	64456831
Cerebral haemorrhage	37.88	11.64	94	41272	50996	64406370
Shock haemorrhagic	37.56	11.64	50	41316	16741	64440625
Vessel puncture site bruise	37.55	11.64	13	41353	411	64456955
Venous pressure jugular decreased	36.40	11.64	9	41357	82	64457284
Hepatitis cholestatic	34.87	11.64	41	41325	12114	64445252
Ovarian hyperstimulation syndrome	34.60	11.64	22	41344	2823	64454543
Aplasia	33.58	11.64	31	41335	6922	64450444
Musculoskeletal stiffness	32.98	11.64	19	41347	123187	64334179
Discomfort	32.95	11.64	6	41360	80872	64376494
Treatment failure	32.75	11.64	17	41349	116799	64340567
Hyponatraemia	32.60	11.64	184	41182	148155	64309211
Therapeutic product effect incomplete	32.21	11.64	13	41353	103469	64353897
Pituitary tumour	31.48	11.64	15	41351	1091	64456275
Pulmonary sarcoidosis	31.17	11.64	15	41351	1116	64456250
Body dysmorphic disorder	31.14	11.64	10	41356	249	64457117
Dizziness	31.12	11.64	156	41210	430007	64027359
Mucosal inflammation	30.56	11.64	99	41267	62485	64394881
Thrombosis	30.31	11.64	107	41259	70535	64386831
Neoplasm progression	29.97	11.64	75	41291	40889	64416477
Haematemesis	29.24	11.64	81	41285	46918	64410448
Systemic lupus erythematosus	29.07	11.64	7	41359	77605	64379761
Adrenal suppression	28.89	11.64	15	41351	1312	64456054
Phlebitis	28.86	11.64	30	41336	7736	64449630
Diarrhoea	28.77	11.64	635	40731	722069	63735297
Glossodynia	28.15	11.64	4	41362	64692	64392674
Haematoma muscle	27.28	11.64	16	41350	1777	64455589
Fatigue	27.07	11.64	329	41037	748401	63708965
Thrombophlebitis	26.90	11.64	25	41341	5629	64451737
Suspected product quality issue	26.60	11.64	9	41357	265	64457101
Dermatitis exfoliative	26.56	11.64	33	41333	10319	64447047
Drug hypersensitivity	26.55	11.64	72	41294	237743	64219623
Gastrointestinal haemorrhage	26.40	11.64	160	41206	132152	64325214
Hypothalamo-pituitary disorder	26.23	11.64	13	41353	1031	64456335
Insomnia	25.97	11.64	55	41311	197781	64259585
Hepatic haematoma	25.95	11.64	12	41354	816	64456550
Blood alkaline phosphatase increased	25.67	11.64	87	41279	56192	64401174
Lung cancer metastatic	25.66	11.64	19	41347	3121	64454245
Intra-abdominal haemorrhage	25.58	11.64	21	41345	4010	64453356
Bronchial obstruction	25.54	11.64	17	41349	2357	64455009
Intentional overdose	25.34	11.64	13	41353	89931	64367435
Peritonitis	25.20	11.64	52	41314	24971	64432395
Bronchial disorder	24.84	11.64	16	41350	2099	64455267
Splenic vein thrombosis	24.55	11.64	11	41355	695	64456671
Needle issue	24.51	11.64	30	41336	9242	64448124
Alopecia	24.41	11.64	43	41323	165647	64291719
Abdominal wall haematoma	24.37	11.64	21	41345	4284	64453082
Retroperitoneal haemorrhage	24.08	11.64	22	41344	4846	64452520
Infusion related reaction	23.94	11.64	43	41323	164424	64292942
Limbal swelling	23.93	11.64	5	41361	19	64457347
Activated partial thromboplastin time prolonged	23.91	11.64	35	41331	12796	64444570
Pneumothorax traumatic	23.89	11.64	8	41358	228	64457138
Hypersensitivity	23.84	11.64	57	41309	196395	64260971
Cardiomyopathy acute	23.70	11.64	8	41358	234	64457132
Joint ankylosis	23.65	11.64	11	41355	758	64456608
Portal vein thrombosis	23.61	11.64	22	41344	4969	64452397
Haemolysis	23.36	11.64	32	41334	11007	64446359
Bone marrow eosinophilic leukocyte count increased	23.35	11.64	5	41361	22	64457344
Clostridium difficile colitis	23.33	11.64	53	41313	27170	64430196
Therapeutic response decreased	23.25	11.64	3	41363	52185	64405181
Death	23.24	11.64	198	41168	482507	63974859
Gastric antral vascular ectasia	23.13	11.64	11	41355	797	64456569
Nasal congestion	23.10	11.64	5	41361	59653	64397713
Oesophagitis	23.03	11.64	46	41320	21584	64435782
Klebsiella infection	22.99	11.64	35	41331	13246	64444120
Hepatic cytolysis	22.89	11.64	36	41330	14013	64443353
Hypokalaemia	22.80	11.64	145	41221	121758	64335608
Compartment syndrome	22.66	11.64	20	41346	4212	64453154
Septic shock	22.64	11.64	130	41236	105307	64352059
Subcutaneous haematoma	22.51	11.64	16	41350	2467	64454899
Gait disturbance	22.47	11.64	48	41318	172107	64285259
Perforation	22.23	11.64	12	41354	1136	64456230
Fracture blisters	22.19	11.64	6	41360	80	64457286
Ventricular fibrillation	22.19	11.64	48	41318	23812	64433554
Peritoneal haematoma	22.01	11.64	7	41359	169	64457197
Haemolytic anaemia	21.93	11.64	38	41328	16015	64441351
Allergic hepatitis	21.91	11.64	5	41361	31	64457335
Wound	21.62	11.64	11	41355	76466	64380900
Hyperthermia	21.49	11.64	37	41329	15513	64441853
Catheter site thrombosis	21.23	11.64	7	41359	190	64457176
Leukopenia	21.20	11.64	124	41242	101118	64356248
Asthma	21.10	11.64	18	41348	95207	64362159
Chondrocalcinosis	21.08	11.64	10	41356	720	64456646
Cytokine release syndrome	20.64	11.64	43	41323	20786	64436580
Thrombocytosis	20.30	11.64	24	41342	7132	64450234
Reading disorder	20.06	11.64	10	41356	803	64456563
Hypertrophic osteoarthropathy	19.88	11.64	6	41360	121	64457245
Abdominal wall haemorrhage	19.31	11.64	8	41358	417	64456949
Upper gastrointestinal haemorrhage	19.30	11.64	58	41308	35162	64422204
Myalgia	19.26	11.64	46	41320	158571	64298795
Eosinophil percentage decreased	19.07	11.64	7	41359	263	64457103
Pulmonary artery thrombosis	18.98	11.64	11	41355	1195	64456171
Retroperitoneal haematoma	18.96	11.64	19	41347	4692	64452674
Suicide attempt	18.93	11.64	11	41355	70996	64386370
Livedo reticularis	18.86	11.64	17	41349	3680	64453686
Pulmonary infarction	18.82	11.64	16	41350	3206	64454160
Pleural effusion	18.63	11.64	142	41224	126417	64330949
Neutropenic infection	18.60	11.64	13	41353	1952	64455414
Ill-defined disorder	18.53	11.64	3	41363	44049	64413317
Haemorrhagic erosive gastritis	18.40	11.64	8	41358	470	64456896
Hospitalisation	18.20	11.64	13	41353	75194	64382172
Pain	18.18	11.64	248	41118	553263	63904103
Psoriatic arthropathy	18.09	11.64	3	41363	43278	64414088
Lung disorder	18.04	11.64	82	41284	60618	64396748
Dysgraphia	17.79	11.64	16	41350	3455	64453911
Metastatic malignant melanoma	17.74	11.64	14	41352	2527	64454839
Bladder tamponade	17.65	11.64	8	41358	519	64456847
Intracranial pressure increased	17.49	11.64	22	41344	6967	64450399
Pneumobilia	17.44	11.64	6	41360	186	64457180
Stress	17.42	11.64	81	41285	60453	64396913
Basilar artery occlusion	17.17	11.64	6	41360	195	64457171
Engraftment syndrome	17.11	11.64	10	41356	1103	64456263
Cerebral haematoma	17.00	11.64	22	41344	7163	64450203
Coagulation factor VII level decreased	16.94	11.64	6	41360	203	64457163
Acute polyneuropathy	16.66	11.64	7	41359	378	64456988
Pain in jaw	16.65	11.64	3	41363	40752	64416614
Femoral neck fracture	16.55	11.64	24	41342	8700	64448666
Rectal haemorrhage	16.54	11.64	81	41285	61736	64395630
Injection site pain	16.32	11.64	29	41337	111379	64345987
Hypovolaemic shock	16.30	11.64	26	41340	10240	64447126
Transaminases increased	16.17	11.64	64	41302	44530	64412836
Antinuclear antibody positive	16.16	11.64	20	41346	6230	64451136
Treatment noncompliance	16.13	11.64	4	41362	43478	64413888
International normalised ratio increased	15.95	11.64	96	41270	79071	64378295
Anaemia folate deficiency	15.89	11.64	6	41360	244	64457122
Varices oesophageal	15.88	11.64	18	41348	5112	64452254
Vomiting	15.87	11.64	464	40902	550653	63906713
Overdose	15.85	11.64	51	41315	159515	64297851
Febrile bone marrow aplasia	15.84	11.64	27	41339	11228	64446138
Erysipelas	15.81	11.64	24	41342	9057	64448309
Alanine aminotransferase increased	15.70	11.64	147	41219	138884	64318482
Intentional product misuse	15.61	11.64	14	41352	72281	64385085
Cardiac failure	15.47	11.64	141	41225	132232	64325134
Adverse drug reaction	15.35	11.64	5	41361	45459	64411907
Penile necrosis	15.34	11.64	4	41362	46	64457320
Myositis	15.29	11.64	33	41333	16344	64441022
Balance disorder	15.06	11.64	19	41347	83907	64373459
Weight increased	15.03	11.64	78	41288	213270	64244096
Haemorrhagic disorder	15.01	11.64	10	41356	1389	64455977
Injection site erythema	14.95	11.64	14	41352	70786	64386580
Exposure during pregnancy	14.90	11.64	93	41273	77582	64379784
Mobility decreased	14.82	11.64	20	41346	85820	64371546
International normalised ratio decreased	14.81	11.64	21	41345	7457	64449909
Erythema	14.71	11.64	184	41182	186886	64270480
Influenza like illness	14.50	11.64	11	41355	61691	64395675
Blood cholesterol increased	14.46	11.64	7	41359	50059	64407307
Mean cell volume increased	14.44	11.64	17	41349	5029	64452337
Peripheral swelling	14.44	11.64	77	41289	209076	64248290
Cholecystitis	14.41	11.64	36	41330	19600	64437766
Lordosis	14.30	11.64	6	41360	323	64457043
Wrong strength	14.30	11.64	5	41361	163	64457203
Granulocyte count increased	14.25	11.64	8	41358	818	64456548
Magnetic resonance imaging head abnormal	14.13	11.64	12	41354	2400	64454966
Protein C decreased	14.12	11.64	4	41362	64	64457302
Viral infection	14.05	11.64	3	41363	36137	64421229
Psychiatric decompensation	13.91	11.64	12	41354	2451	64454915
Chemotherapeutic drug level increased	13.91	11.64	6	41360	346	64457020
Jaundice cholestatic	13.82	11.64	22	41344	8648	64448718
Pain in extremity	13.81	11.64	126	41240	302959	64154407
Migraine	13.70	11.64	12	41354	62665	64394701
Drug interaction	13.65	11.64	316	41050	361767	64095599
Influenza	13.65	11.64	30	41336	106501	64350865
Drug resistance	13.47	11.64	3	41363	35099	64422267
Loss of personal independence in daily activities	13.42	11.64	16	41350	72438	64384928
Lactic acidosis	13.36	11.64	76	41290	61334	64396032
Respiratory disorder	13.23	11.64	52	41314	36059	64421307
Duodenal ulcer perforation	13.21	11.64	3	41363	34622	64422744
Unevaluable event	13.20	11.64	8	41358	50481	64406885
Sudden hearing loss	13.20	11.64	10	41356	1700	64455666
Staphylococcal scalded skin syndrome	13.17	11.64	6	41360	394	64456972
Injury	13.13	11.64	10	41356	55982	64401384
Blood creatinine increased	13.11	11.64	139	41227	135643	64321723
Thrombosis prophylaxis	13.09	11.64	3	41363	19	64457347
Suicidal ideation	13.08	11.64	14	41352	66528	64390838
Mental status changes	13.02	11.64	12	41354	61150	64396216
Disseminated intravascular coagulation	13.02	11.64	48	41318	32300	64425066
Respiratory distress	12.89	11.64	67	41299	52264	64405102
Visual acuity reduced transiently	12.87	11.64	5	41361	220	64457146
Protein S decreased	12.84	11.64	4	41362	90	64457276
Hyperlipasaemia	12.76	11.64	8	41358	1002	64456364
Gastrointestinal stoma output increased	12.68	11.64	5	41361	229	64457137
Eosinophilia	12.50	11.64	53	41313	38023	64419343
CSF white blood cell count decreased	12.48	11.64	3	41363	24	64457342
Post procedural pulmonary embolism	12.46	11.64	5	41361	240	64457126
Electrolyte imbalance	12.38	11.64	40	41326	25203	64432163
Prostatitis Escherichia coli	12.37	11.64	3	41363	25	64457341
IIIrd nerve disorder	12.37	11.64	4	41362	102	64457264
Superior vena cava syndrome	12.30	11.64	8	41358	1067	64456299
Injection site bruising	12.28	11.64	4	41362	36369	64420997
Haemoptysis	12.22	11.64	63	41303	48985	64408381
Swelling	12.19	11.64	57	41309	160161	64297205
Gastrointestinal tract adenoma	12.18	11.64	6	41360	470	64456896
Throat irritation	12.15	11.64	3	41363	32708	64424658
Soft tissue sarcoma	12.12	11.64	4	41362	109	64457257
Emotional distress	12.10	11.64	4	41362	36034	64421332
HER2 positive breast cancer	12.04	11.64	5	41361	262	64457104
Therapy cessation	12.03	11.64	3	41363	32486	64424880
Nasopharyngitis	12.02	11.64	75	41291	195998	64261368
Faecaloma	11.97	11.64	22	41344	9706	64447660
Renal tubular acidosis	11.96	11.64	12	41354	2967	64454399
Malnutrition	11.93	11.64	33	41333	19092	64438274
Interstitial lung disease	11.87	11.64	105	41261	97627	64359739
Intra-abdominal haematoma	11.87	11.64	11	41355	2468	64454898
Fall	11.85	11.64	192	41174	416634	64040732
Reticulocyte count increased	11.72	11.64	8	41358	1156	64456210
Gastrointestinal disorder	11.71	11.64	25	41341	89684	64367682
Gastrointestinal ulcer perforation	11.71	11.64	3	41363	32	64457334

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AB10	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Heparin group
ATC	B01AB12	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Heparin group
FDA CS	M0010191	Heparin, Low-Molecular-Weight
FDA EPC	N0000175586	Low Molecular Weight Heparin
MeSH PA	D000925	Anticoagulants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D005343	Fibrinolytic Agents
MeSH PA	D006401	Hematologic Agents
CHEBI has role	CHEBI:50249	anticoagulants

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Pulmonary embolism	indication	59282003	DOID:9477
Deep venous thrombosis	indication	128053003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10,000IU/0.4ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	DISCN	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
10,000IU/ML (10,000IU/ML)	FRAGMIN	PFIZER	N020287	Jan. 30, 1998	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
12,500IU/0.5ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
15,000IU/0.6ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
18,000IU/0.72ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	May 1, 2007	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
2,500IU/0.2ML (12,500IU/ML)	FRAGMIN	PFIZER	N020287	Dec. 22, 1994	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
5,000IU/0.2ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	March 18, 1996	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
7,500 IU/0.75ML	FRAGMIN	PFIZER	N020287	April 4, 2002	DISCN	INJECTABLE	INJECTION	May 16, 2022	NEW PATIENT POPULATION
7,500IU/0.3ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	April 4, 2002	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
95,000IU/3.8ML (25,000IU/ML)	FRAGMIN	PFIZER	N020287	April 4, 2002	RX	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION
95,000IU/9.5ML (10,000IU/ML)	FRAGMIN	PFIZER	N020287	April 4, 2002	DISCN	INJECTABLE	SUBCUTANEOUS	May 16, 2022	NEW PATIENT POPULATION

Bioactivity Summary:

None

External reference:

ID	Source
PUE0TO3XDR	UNII
4020894	VANDF
4021054	VANDF
4021237	VANDF
4024199	VANDF
C0916062	UMLSCUI
CHEBI:28304	CHEBI
CHEMBL3707365	ChEMBL_ID
772	PUBCHEM_CID
DB09258	DRUGBANK_ID
CHEMBL4650299	ChEMBL_ID
CHEMBL1201414	ChEMBL_ID
CHEMBL1201448	ChEMBL_ID
CHEMBL1201460	ChEMBL_ID
CHEMBL2108806	ChEMBL_ID
C411345	MESH_SUPPLEMENTAL_RECORD_UI
C093450	MESH_SUPPLEMENTAL_RECORD_UI
6846	IUPHAR_LIGAND_ID
9005-49-6	SECONDARY_CAS_RN
DB06822	DRUGBANK_ID
104466	RXNORM
15471	MMSL
4531	MMSL
d04659	MMSL
005078	NDDF
007911	NDDF
008338	NDDF
108987000	SNOMEDCT_US
108990006	SNOMEDCT_US
350469004	SNOMEDCT_US
395908006	SNOMEDCT_US
410964003	SNOMEDCT_US
410965002	SNOMEDCT_US
410967005	SNOMEDCT_US
412608008	SNOMEDCT_US
D000078222	MESH_DESCRIPTOR_UI
D017985	MESH_DESCRIPTOR_UI
6985	INN_ID
5688	INN_ID
6764	INN_ID
7501	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0195	INJECTION	2500 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0196	INJECTION	5000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0206	INJECTION	7500 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0217	INJECTION	10000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0220	INJECTION	12500 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0223	INJECTION	15000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0228	INJECTION	18000 [iU]	SUBCUTANEOUS	NDA	28 sections
Fragmin	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0232	INJECTION	25000 [iU]	SUBCUTANEOUS	NDA	28 sections